TII
2.8.2021 15:56:08 CEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), the overarching advanced technology body in Abu Dhabi responsible for driving research and development for transformative technology outcomes, today announced the appointment of veteran technologist and entrepreneur Dr Ray O. Johnson as Chief Executive Officer. Dr Johnson will work on shaping the strategic direction of the Institute and lead the execution of its growth strategies to achieve operational excellence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005462/en/
Prior to joining TII, Dr Johnson was an Operating Partner at Bessemer Venture Partners, a top-tier American venture capital company that has been part of 130 IPOs in the last 50 years, and before that, he was the Corporate Senior Vice President for Engineering, Technology, and Operations and Chief Technology Officer of the Lockheed Martin Corporation.
Dr Johnson brings to his role over four decades of experience in global technology leadership, making strategic investments in disruptive technologies, and developing business strategies that resulted in several new billion-dollar lines of business. He also holds outstanding networking capabilities; he has met with leaders at the highest echelons of government, industry, and academia. He is frequently sought after as a speaker at global forums on business, strategy, innovation, and education.
Speaking on the new appointment, His Excellency Faisal Al Bannai, Secretary General of ATRC, said: “We welcome Dr Ray Johnson as the first CEO of Technology Innovation Institute. His appointment is a much anticipated one – we were keen that the person entrusted with this role should not merely be an excellent research and technology specialist, but equally, a consummate professional and industry stakeholder that is capable of ensuring the most positive outcomes for the breakthrough projects TII is currently engaged in across its seven initial dedicated research centres.
“We are confident Dr Johnson will be able to build game-changing synergies for TII as he leads it towards realising its wider goals of growing its talented global team of 375+ researchers, scientists, and engineers, and ensuring the objectives of the current workstreams are met. He will also leverage his vast network to further expand our visibility and reach across markets.”
For his part, Dr Ray O. Johnson said: “I am very excited about this new role in a region that I admire for its dedication to advanced research and development for the betterment of the UAE. Since TII’s inception in November 2020, I have followed its many announcements and achievements with great interest. As it moves into a new phase of growth, I look forward to working with the talented teams of researchers across its centres to drive competitive results and facilitate breakthrough solutions that transition to the market.”
Technology Innovation Institute (TII) is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy, and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE, reinforces the status of Abu Dhabi and the UAE as a global hub for innovation, and contributes to the broader development of the knowledge-based economy.
For information on Advanced Technology Research Council (ATRC), visit www.atrc.ae
For information on Technology Innovation Institute (TII), visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005462/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
